StockUS listing USENLVNASDAQHealthcareProfitless Growth

Enlivex Therapeutics Ltd(ENLV) Stock Analysis | Healthcare

USD --+0.00%
Reward62Moderate
Risk69Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 2.01M
Reward Ratingⓘ62 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ69 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ENLV to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Enlivex Therapeutics Ltd?

, together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

AI Brief Pro

The brief on Enlivex Therapeutics Ltd

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Enlivex Therapeutics Ltd?

, together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.01M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (62)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio0.0001
Beta1.609
Insider Activity
12M windowNo data
No insider activity data available for this ticker.